In the context of EGFR–driven lung tumorigenesis, MIG6, an EGFR–negative regulator, acts as a tumor suppressor by downregulating EGFR signaling, highlighting the emerging research focusing on the interplay between AXL, MIG6 and EGFR in NSCLC. The gene discussed is AXL; the disease is neoplasm.